2019 Policy Updates
Addendum to the 4th Edition of the Malawi Integrated Guidelines and Standard Operating Procedures for Clinical HIV Services
Contents

8  HIV-related diseases ............................................................................................................. 6
  8.1  Routine urine LAM and serum CrAg screening ................................................................. 6
  •  Serum CrAg .......................................................................................................................... 6
  8.2  Management of HIV-related diseases ............................................................................. 6
  8.2.1  Cryptococcal meningitis (CM) ....................................................................................... 6
  8.2.2  Cryptococcaemia ........................................................................................................... 7

10  Preventive Services for HIV patients ............................................................................... 8
  10.3  TB Preventive Therapy .................................................................................................. 8
  10.3.1  Dispensing TPT ........................................................................................................... 9

11  Understanding ART regimens and formulations ............................................................ 10
  11.2  Choosing ART regimen, formulation and dosage ......................................................... 11
  11.2.3  Start regimen .............................................................................................................. 11
  11.2.10  Use of DTG or EFV in women of reproductive age .................................................. 12
  11.2.12  How to give LPV/r granules ...................................................................................... 12

14  Combining ART and TB treatment ................................................................................. 17

15  Continuing ART ................................................................................................................ 17
  15.7  Achieving optimal adherence .......................................................................................... 17
  15.7.3  Supporting children on LPV/r granules .................................................................... 17
  15.10  Monitoring for treatment failure / HIV drug resistance .............................................. 18
  15.10.2  Viral load (VL) testing .............................................................................................. 18

16  Differentiated ART services ............................................................................................. 23
  16.1  Six months ARV dispensing (6MD) visits ..................................................................... 23

19  Transition to new ART regimen ....................................................................................... 24
  19.2  Transition for patients currently on ART ..................................................................... 24

20  Pre-exposure prophylaxis (PrEP) ...................................................................................... 26
Contents

Tables
Table 1: Contraindications for IPT and 3HP .................................................................................. 9
Table 10: Selection of standard ART regimen for initiation .......................................................... 11
Table 11: Standard ART Regimens (all strengths in mg) ................................................................ 14
Table 12: Standard pack sizes and dosing of Paediatric and Adult formulations of ARVs, TPT and CPT ...................................................................................................................... 16
Table 13 (new): Classification of DBS and plasma VL results ....................................................... 19

Figures
Figure 5: Indication, interpretation and action for routine scheduled and targeted VL testing .................................................................................................................................................. 22
Figure 6: Alignment of 6 months dispensing with 12-monthly VL monitoring ............................ 23
Figure 7: Regimen transition for all remaining children, women and men in 2019/2020 .......... 25
Foreword

This addendum includes detailed policy updates for the 2018 Clinical Management of HIV in Children and Adults guidelines.

The updates apply from April 2019 until publication of the next guideline edition which is scheduled for late 2020.

This addendum does not fully replace the 4th edition of Clinical Management of HIV in Children and Adults guidelines for Malawi of 2018, but it should be used side-by-side with the 2018 guidelines. Updated content is shown using the same section numbering as in the main guideline document and this replaces the respective section.

Oral Pre-Exposure Prophylaxis for HIV (PrEP) has been included as it relates to the prescription and monitoring of ARVs in Malawi. However, a detailed PrEP implementation guideline will be published as a separate document.
## Acronyms and Abbreviations

<table>
<thead>
<tr>
<th>Acronym</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>3TC</td>
<td>Lamivudine</td>
</tr>
<tr>
<td>3HP</td>
<td>3 months short course of isoniazid rifapentine TB preventive therapy</td>
</tr>
<tr>
<td>6MD</td>
<td>6 month dispensing / ART clinic appointment spacing</td>
</tr>
<tr>
<td>ABC</td>
<td>Abacavir</td>
</tr>
<tr>
<td>ART</td>
<td>Antiretroviral therapy</td>
</tr>
<tr>
<td>ARV</td>
<td>Antiretroviral medicines</td>
</tr>
<tr>
<td>ATV/r</td>
<td>Atazanavir and ritonavir fixed dose combination</td>
</tr>
<tr>
<td>AZT</td>
<td>Zidovudine</td>
</tr>
<tr>
<td>DBS</td>
<td>Dried blood spot</td>
</tr>
<tr>
<td>DSD</td>
<td>Differentiated service delivery</td>
</tr>
<tr>
<td>DTG</td>
<td>Dolutegravir</td>
</tr>
<tr>
<td>FeFol</td>
<td>Iron and folate supplement</td>
</tr>
<tr>
<td>Efavirenz</td>
<td>Efavirenz</td>
</tr>
<tr>
<td>H</td>
<td>Isoniazid</td>
</tr>
<tr>
<td>HIV</td>
<td>Human immunodeficiency virus</td>
</tr>
<tr>
<td>IAC</td>
<td>Intensive adherence counseling</td>
</tr>
<tr>
<td>INH</td>
<td>Isoniazid</td>
</tr>
<tr>
<td>IPT</td>
<td>Isoniazid preventive therapy</td>
</tr>
<tr>
<td>LDL</td>
<td>Lower detection limit (for viral load)</td>
</tr>
<tr>
<td>LPV/r</td>
<td>Lopinavir and ritonavir fixed dose combination</td>
</tr>
<tr>
<td>NNRTI</td>
<td>Non-nucleoside reverse transcriptase inhibitor</td>
</tr>
<tr>
<td>NRTI</td>
<td>Nucleoside reverse transcriptase inhibitor</td>
</tr>
<tr>
<td>NVP</td>
<td>Nevirapine</td>
</tr>
<tr>
<td>PI</td>
<td>Protease inhibitor</td>
</tr>
<tr>
<td>PLHIV</td>
<td>People living with HIV</td>
</tr>
<tr>
<td>PMTCT</td>
<td>Prevention of mother to child transmission</td>
</tr>
<tr>
<td>PrEP</td>
<td>Pre-exposure prophylaxis for HIV using antiretroviral medicines</td>
</tr>
<tr>
<td>RAL</td>
<td>Raltegravir</td>
</tr>
<tr>
<td>RFP</td>
<td>Rifapentine (used in 3HP)</td>
</tr>
<tr>
<td>TDF</td>
<td>Tenofovir disoproxil fumarate</td>
</tr>
<tr>
<td>TPT</td>
<td>Tuberculosis (TB) preventive therapy</td>
</tr>
<tr>
<td>TST</td>
<td>Tuberculin skin test</td>
</tr>
<tr>
<td>VL</td>
<td>Viral load</td>
</tr>
</tbody>
</table>
### Summary of Policy Updates

<table>
<thead>
<tr>
<th>Section</th>
<th>Policy</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>8.2.1</td>
<td>Use Liposomal Amphotericin B and Flucytosine as the preferred option for treating Cryptococcal meningitis.</td>
<td>6</td>
</tr>
<tr>
<td>10.3</td>
<td><strong>TPT transition Phase 1 (immediate):</strong> Once sufficient stocks of INH and pyridoxine have been distributed, give a 6 month course of IPT to all new and all current patients on ART in all districts. Patients who have already completed 6 months or more of IPT in the 5 districts implementing the continuous IPT policy (2016-2019) are exempt.</td>
<td>8</td>
</tr>
<tr>
<td></td>
<td><strong>TPT transition Phase 2 (from mid-2020):</strong> Once available, give a single short course of isoniazid and rifapentine (3HP) to all new patients on ART in all districts. Take one weekly dose of isoniazid + rifapentine (every 7 days) for 3 months, completing a total of 12 doses. Exempt patients who have already completed 6 months or more of IPT. 3HP is currently not given to children, pregnant women and patients on PI-based ART.</td>
<td></td>
</tr>
<tr>
<td>11.2.10</td>
<td>Recommend DTG-based regimens for all patients from 20kg+, including women who may get pregnant while on ART.</td>
<td>12</td>
</tr>
<tr>
<td>15.10</td>
<td>Routinely monitor VL at 6 months after starting ART and then every 12 months from the last test. Follow updated guidelines for interpretation of VL results.</td>
<td>18</td>
</tr>
<tr>
<td>15.10.2</td>
<td>Deliver one quality session of intensive adherence counselling (IAC) at the same visit when returning a detectable VL result to the patient. Give a regular 3-month appointment to collect the follow-up VL. Provide additional IAC sessions at 1 month intervals if needed.</td>
<td>19</td>
</tr>
<tr>
<td>16</td>
<td>Routinely give 6-month ART clinic appointments for uncomplicated and stable patients. Dispense regimen 13A in 90 tablet (3-month) packs for 3 and 6 month appointments.</td>
<td>23</td>
</tr>
<tr>
<td>19</td>
<td>Transition all children from NVP-based regimens to LPV/r-based regimen or a suitable alternative.</td>
<td>24</td>
</tr>
<tr>
<td>20</td>
<td>Offer oral PrEP as additional prevention method for HIV-negative clients at substantial risk of HIV infection.</td>
<td>26</td>
</tr>
</tbody>
</table>
8 HIV-related diseases

8.1 Routine urine LAM and serum CrAg screening

- Serum CrAg
  - Positive: Do Lumbar Puncture (LP), treat for active meningitis if CSF testing (CrAg, Indian ink, Xpert) result is positive. If CSF testing result is negative, give pre-emptive anti-fungal therapy for cryptococcaemia (see section 8.2.2)

8.2 Management of HIV-related diseases

8.2.1 Cryptococcal meningitis (CM)

Key Facts: Cryptococcal meningitis (CM)

- Early diagnosis and treatment are life-saving.
- Liposomal amphotericin B has much lower toxicity than the regular amphotericin B deoxycholate. This means it can be given at higher doses which is more effective.
- Liposomal amphotericin B will be distributed to central, district and large mission hospitals from early 2020. Call the HIV Department logistics hotline for ad-hoc supplies.

Primary Management

**Admit**

Daily therapeutic spinal tap if high intracranial pressure, severe headache or vomiting is present (up to 30 ml per puncture).

If not already on ART, start ART only **5 weeks** after anti-fungal treatment initiation.

**Induction phase**

Do not give adjunctive corticosteroids during induction treatment.

**Option 1: Liposomal AmphotericinB**

| For 7 days | Preferred option if both meds are available |

Liposomal Amphotericin B

- **Adult:** 3 – 4 mg/kg IV over 6 hours 24-hourly. Use up to 6 mg/kg for treatment failure or serious disease.
- **Child:** 6mg/kg IV over 6 hours 24-hourly.

Flucytosine tabs

100mg/kg/day divided into 4 doses (6-hourly)

**Option 2: Fluconazole + Flucytosine for 14 days**

This option requires FBC monitoring: at baseline and 2-3 times in the second week of treatment.

**Fluconazole tabs**

- **Adult:** 1200mg 24-hourly
- **Child:** 12mg/kg (max 800mg) 24-hourly

**Flucytosine tabs**

100mg/kg/day divided into 4 doses (6-hourly)

Before giving **Liposomal Amphotericin B:** Pre-hydrate and supplement electrolytes: 1000ml NS (weight-based for children) + Potassium 2 tabs 12-hourly + Magnesium trisilicate 1 tabs 24-hourly in the evening.

Do not combine **Liposomal Amphotericin B** with **TDF-based** ART (5A, 6A, 7A, 10A, 13A). Substitute for ABC-based regimen if already on ART.
Option 3: Liposomal Amphotericin B + Fluconazole for 14 days

This option requires FBC, Creatinine and K+ monitoring: at baseline and 2-3 times in the second week of treatment.

Liposomal Amphotericin B

3 – 4 mg/kg IV over 6 hours 24-hourly
Use up to 6 mg/kg for treatment failure or serious disease.

Fluconazole tabs

Adult: 1200mg 24-hourly
Child: 12mg/kg (max 800mg) 24-hourly

Consolidation phase

Fluconazole tabs for 8 weeks

Adult: 800mg 24-hourly
Child: 12mg/kg (max 800mg) 24-hourly

Maintenance phase

Fluconazole tabs, lifelong

Adult: 200mg 24-hourly
Child: 6mg/kg 24-hourly

8.2.2 Cryptococcaemia

Clinical signs

Often no clinical signs. Note: the lack of meningitis signs does not rule out active CM

Diagnosis/investigations

Serum CrAg test positive but CSF is negative for CrAg and/or microscopy (Indian ink).

Assess for meningitis signs. If positive, do full investigation and treatment for active CM (see section 8.2.1). If negative, but patient is symptomatic treat for active CM

Primary management

Fluconazole tablets

800 mg 24-hourly for 2 weeks then
400 mg 24-hourly for 8 weeks then
200mg 24-hourly for life
Preventive Services for HIV patients

10.3 TB Preventive Therapy

**Key Facts: TB Preventive Therapy (TPT)**

- A single course of TPT can prevent active TB in people who are at high risk. Give TPT to:
  - HIV infected children and adults regardless of TST status (if known).
  - Children under 5 years – regardless of HIV status - who live with a patient being treated for TB (sputum positive or negative, or LAM positive): give 6 months course of IPT.

- HIV patients who have completed 6 months of IPT in the past (during pre-ART or ART) do not need another course of TPT.

- Do not give TPT to a patient who has any signs suggestive of active TB: such patients need full investigation for TB and combination TB treatment to avoid TB drug resistance.
  - New patients: Start TPT together with ART and CPT.
  - Already on ART: Start TPT regardless of the time on ART.
  - Give TPT regardless of previous TB treatment.

- Two alternative TPT options are similarly effective:
  - **6H**: 6-month course of daily dose of isoniazid:
    - Immediately available, suitable for children, not suitable for pregnant women
    - Can be combined with all ART regimens
  - **3HP**: 3-month course of weekly doses of isoniazid + rifapentine
    - Available from mid-2020
    - Easier to complete due to short duration.
    - Not suitable for children under 20kg and pregnant women, cannot be combined with PI-based ART regimens
    - Women on hormonal contraception need to use condoms while on 3HP. Rifapentine reduces contraceptive effectiveness.

- TPT is well tolerated by 95% of patients. Most side effects are mild and disappear within 3 months. Serious side effects are rare: hypersensitivity, neuropathy and severe hepatitis.

- Stop TPT if any of the following are seen:
  - Nausea, vomiting, loss of appetite
  - Pellagra-type skin rash in sun-exposed areas and other severe skin rash
  - Yellow eyes
  - Dizziness / confusion / convulsions
  - Severe numbness/burning pain and muscular weakness of legs and/or arms
10.3.1 Dispensing TPT

- Patients who have already completed 6 months or more of IPT in the past are exempt.
- Emphasize adherence during treatment.
- Ensure proper documentation on patient card.
- Always give pyridoxine to prevent neuropathy. **Don’t prescribe TPT if pyridoxine is not available.**
- Stop immediately if clients develop severe peripheral neuropathy, hypersensitivity reactions, gastrointestinal intolerance and hepatotoxicity.
- Report to the health facility immediately with nausea and loss of appetite. These are early warning signs of hepatotoxicity.

IPT: (TPT Phase 1) Start from October 2019

- Once sufficient stocks of INH and pyridoxine have been distributed, give a single 6 month course of IPT to all new and all current patients on ART in all districts.
- Give 1 daily dose of INH and pyridoxine for 6 months (cumulative total of at least 168 daily doses).
- Give 1 daily tablet of pyridoxine 24-hourly. **Adults:** 25 or 50mg. **Children <20kg:** about 1mg/kg
- Review patients at **month 1, 3 and 6** after starting IPT for any side effects and monitor adherence.

3HP: (TPT Phase 2) Start from mid-2020

- Once rifapentine is available, give a single course of 12 weekly doses of isoniazid and rifapentine (3HP) as TB preventive therapy to all new patients on ART in all districts.
- All clients newly initiated on ART in all districts who are 20kg+ and can swallow tablets whole without crushing/chewing are eligible for 3HP.
- Give weekly doses of rifapentine + isoniazid for 12 weeks based on weight (see **Table 12 on page 16**).
- Give 1 daily tablet of pyridoxine 24-hourly. **Adults:** 25 or 50mg. **Children <20kg:** about 1mg/kg
- Advise women on hormonal contraceptives to use condoms while on 3HP.
- Review patients at **month 1, 2 and 3** after starting 3HP for any side effects and monitor adherence.

**TPT Contraindications**

**Table 1: Contraindications for IPT and 3HP**

<table>
<thead>
<tr>
<th>IPT and 3HP</th>
<th>3HP</th>
</tr>
</thead>
<tbody>
<tr>
<td>Suspected or confirmed active TB</td>
<td>Prior adverse events or hypersensitivity to rifapentine or rifampicin.</td>
</tr>
<tr>
<td>Prior adverse events or hypersensitivity to INH</td>
<td>Children under 20kg: almost all will now be on LPV/r based regimens, which cannot be combined with 3HP.</td>
</tr>
<tr>
<td>Active hepatitis, liver damage, heavy alcohol use</td>
<td>Unable to swallow a tablet without crushing/chewing.</td>
</tr>
<tr>
<td>Severe peripheral neuropathy</td>
<td>PI-based ART regimens</td>
</tr>
<tr>
<td>Pregnant women or women planning to become pregnant during treatment</td>
<td></td>
</tr>
</tbody>
</table>
11 Understanding ART regimens and formulations

Key Facts: Dolutegravir (DTG)

- The general benefits of DTG are now thought to outweigh any potential risks, including for women who may get pregnant while on ART:
  - Faster and more durable viral suppression
  - Lower risk of maternal OIs and death
  - Reduced risk of HIV transmission to sexual partners and to the child
  - The potential risk of neural tube defects is now considered very low.
- Start / transition all children from 20kg+ to a DTG-based regimen. However, note that regimen 13A can only be used from 30kg+ because the dose of TDF is too high for smaller children. Use:
  - 15P for 20.0 – 24.9 kg
  - 15A for 25.0 – 29.9 kg
  - Monitor weight and routinely move children to 13A once they have reached 30kg+
  - Confirm undetectable VL in the last 6 months before making this transition.
- DTG may be associated with increased risk of obesity in some patients.
11.2 Choosing ART regimen, formulation and dosage

Key Facts: NVP-resistance in children

- About half of all children no longer achieve viral suppression on NVP-based ART (regimen 2P)
  - This is mainly due to increasing NNRTI-resistance (NVP, EFV) among children who are getting infected by their mothers.
- Start / transition all children under 20kg to regimen 9P (ABC/3TC + LPV/r)
  - Use LPV/r granules or pellets for children who can’t swallow paediatric LPV/r tablets whole.
  - Caution: LPV/r tablets are not properly absorbed when crushed, chewed or dissolved. This will lead to development of LPV/r resistance.
  - Move to paediatric LPV/r tablets when the child’s ability for swallowing whole has been confirmed.
  - Children and their caregivers may initially struggle to take LPV/r granules due to the relatively large amount and the bitter taste if not quickly swallowed.
  - Probe patiently and thoroughly at every visit to understand if the child is actually swallowing the full dose twice daily as prescribed. Review step-by-step how the granules are opened, prepared and administered.
  - Offer an alternative regimen if the child is not able to reliably take the prescribed dose.
  - Consult the Department of HIV and AIDS for alternative regimens for children on LPV/r-based regimens who need TB treatment.

11.2.3 Start regimen

- Select one of the 3 standard regimens to start patients on ART, based on weight.
- Use alternative 1st line regimens if the patient has any contraindications for the standard regimen.

Table 10: Selection of standard ART regimen for initiation

<table>
<thead>
<tr>
<th>Weight (kg)</th>
<th>Regimen</th>
<th>Conditions / Instructions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Under 3kg</td>
<td>-</td>
<td>No routine ART. Consult DHA in special cases.</td>
</tr>
<tr>
<td>3 – 20kg</td>
<td>9P</td>
<td>Use LPV/r granules for children unable to swallow whole paediatric LPV/r tabs. LPV/r tabs must not be broken, crushed or dissolved.</td>
</tr>
<tr>
<td>20.0 – 24.9kg</td>
<td>15P</td>
<td>Use paediatric ABC/3TC tablet + regular (adult) dose DTG 50mg. Use paediatric patient card (blue)</td>
</tr>
<tr>
<td>25.0 - 29.9kg</td>
<td>15A</td>
<td>Use adult ABC/3TC tablet + regular (adult) dose DTG 50mg. Use adult patient card (yellow)</td>
</tr>
<tr>
<td>30kg +</td>
<td>13A</td>
<td></td>
</tr>
</tbody>
</table>
11.2.10 Use of DTG or EFV in women of reproductive age

- The benefits of DTG outweigh the potential, very low risk of neural tube defects for women who may get pregnant while on ART.

- Use DTG-based regimens as standard 1st line regimens for all patients 20kg+, including girls and women who may get pregnant.
  
  o Explain the general benefits vs. the potential, very low risks of birth defects to all women who want to become pregnant. Offer 5A or alternative regimens if women chose to avoid DTG.

  o Note that 13A can only be used from 30kg+. Use 15P from 20-24.9kg and 15A from 25-29.9kg

11.2.12 How to give LPV/r granules

- LPV/r granules contain the same medication and dose as the LPV/r pellets (in capsules), but the granules are much smaller and a packed in sachets.

1. Take the required number of sachets according to weight (see Table 12 on page 16).

2. Shake the sachet gently to ensure all granules settle towards bottom of packet.

3. Tear open the required number of sachets one after the other and empty granules into a dry cup or bowl. Make sure all granules empty out of packet.

4. Put a small amount of food or expressed breast milk in a separate clean bowl
  
  o Babies 0-5 months: add some granules to spoonful of breastmilk, mix to prevent clumping, nurse after giving each spoonful.

  o Children 6+ months: mix some granules with soft food (mashed banana, avocado, sweet potato, Irish potato, yoghurt, porridge, etc.), feed to the child immediately. Then give the child a small bite of food without medicine.

  o For all: repeat this process until the whole amount of granules has been taken.

5. Don’t forget to give the other part of the regimen (e.g. ABC/3TC)

6. Switch foods often, do not always give with the same food.

7. Bitter taste comes after sitting in liquid/food for several seconds, so give as quickly as possible and follow up with nursing or sweet food to help remove taste.

8. Throw away the empty sachet.
Page left blank intentionally
<table>
<thead>
<tr>
<th>Regimen</th>
<th>P paed. Formulation</th>
<th>Adult Formulation</th>
<th>Used for ART Regimen 'Start regimen'</th>
<th>Line</th>
<th>Prescriber level</th>
<th>‘Tail’ needed</th>
<th>Contraindications</th>
<th>Possible adverse reaction</th>
<th>If confirmed, use Alt 1</th>
<th>Alt 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>4</td>
<td>AZT 60 / 3TC 30 + EFV 200</td>
<td>AZT 300 / 3TC 150 + EFV 600</td>
<td>No</td>
<td>1st</td>
<td>1</td>
<td>Yes</td>
<td>- Anaemia &lt;8g/dl&lt;br&gt;- History of psychosis</td>
<td>- Anaemia, vomiting, appetite loss&lt;br&gt;- Lipodystrophy, lactic acidosis&lt;br&gt;- Hepatitis, rash, psychosis, gynaecomastia</td>
<td>5, 17</td>
<td>13, 15</td>
</tr>
<tr>
<td>5</td>
<td>TDF 300 / 3TC 300 / EFV 600</td>
<td>Alternative for patients with (relative) DTG contraindications</td>
<td>No</td>
<td>2nd</td>
<td>2</td>
<td>No</td>
<td>- History of psychosis&lt;br&gt;- Uncontrolled BP1 / diabetes, renal failure</td>
<td>- Renal failure&lt;br&gt;- Hepatitis, rash, psychosis, gynaecomastia</td>
<td>17c</td>
<td>4, 15c, 14</td>
</tr>
<tr>
<td>7</td>
<td>TDF 300 / 3TC 300 + ATV/r 300/100</td>
<td>No</td>
<td>2nd</td>
<td>2</td>
<td>No</td>
<td>- Uncontrolled BP1 / diabetes, renal failure&lt;br&gt;- Patient on rifampin d&lt;br&gt;- Pre-existing jaundice or suspected hepatitis a</td>
<td>- Renal failure&lt;br&gt;- Jaundice f</td>
<td>15c</td>
<td>11, NS</td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>AZT 300 / 3TC 150 + ATV/r 300/100</td>
<td>No</td>
<td>2nd</td>
<td>2</td>
<td>No</td>
<td>- Anaemia &lt;8g/dl&lt;br&gt;- Patient on rifampin d&lt;br&gt;- Pre-existing jaundice or suspected hepatitis a</td>
<td>- Anaemia, vomiting, appetite loss&lt;br&gt;- Lipodystrophy, Lactic acidosis&lt;br&gt;- Jaundice f&lt;br&gt;- Treatment failure g</td>
<td>11</td>
<td>14, 13</td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>ABC 120 / 3TC 60 + LPV/r 100/25</td>
<td>New standard for children under 20kg</td>
<td></td>
<td>1st or 2nd</td>
<td>1</td>
<td>No</td>
<td>- ABC hypersensitivity</td>
<td>- Fever, body pains, vomiting, cough h&lt;br&gt;- Diarrhoea, vomiting, dizziness, headache</td>
<td>10, 11</td>
<td>14, 13, 8</td>
</tr>
<tr>
<td>10</td>
<td>TDF 300 / 3TC 300 + LPV/r 200/50</td>
<td>No</td>
<td>2nd</td>
<td>2</td>
<td>No</td>
<td>- Uncontrolled BP1 / diabetes, renal failure</td>
<td>- Renal failure&lt;br&gt;- Diarrhoea, vomiting, dizziness, headache&lt;br&gt;- Treatment failure g</td>
<td>14</td>
<td>13, 14, 15</td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>AZT 60 / 3TC 30 + LPV/r 100/25</td>
<td>No</td>
<td>2nd</td>
<td>2</td>
<td>No</td>
<td>- Anaemia &lt;8g/dl</td>
<td>- Anaemia, vomiting, appetite loss&lt;br&gt;- Lipodystrophy, lactic acidosis&lt;br&gt;- Diarrhoea, vomiting, dizziness, headache</td>
<td>8</td>
<td>14</td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>DRV 600 + r 100 + DTG 50 (± NRTIs)</td>
<td>No</td>
<td>3rd</td>
<td>2</td>
<td>No</td>
<td>- Epilepsy i</td>
<td>- Diarrhoea, vomiting, headache, dizziness, insomnia&lt;br&gt;- Neuropathy&lt;br&gt;- Rash, jaundice</td>
<td>NS</td>
<td>NS</td>
<td></td>
</tr>
</tbody>
</table>

**Table 11: Standard ART Regimens** (all strengths in mg)
<table>
<thead>
<tr>
<th>Regimen</th>
<th>13</th>
<th>14</th>
<th>15</th>
<th>16</th>
<th>17</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Regimen</strong></td>
<td>TDF 300 / 3TC 300 / DTG 50</td>
<td>AZT 60 / 3TC 30 + DTG 50</td>
<td>ABC 120 / 3TC 60 + DTG 50</td>
<td>ABC 120 / 3TC 60 + RAL 25</td>
<td>ABC 120 / 3TC 60 + EFV 200</td>
</tr>
<tr>
<td><strong>Paed. Formulation</strong></td>
<td>Standard for all patients 30 kg+</td>
<td>No</td>
<td>Standard for children 20 – 29.9 kg</td>
<td>ABC 600 / 3TC 300 + DTG 50</td>
<td>ABC 600 / 3TC 300 + EFV 600</td>
</tr>
<tr>
<td><strong>Adult Formulation</strong></td>
<td>1st or 2nd</td>
<td>1st or 2nd</td>
<td>1st or 2nd</td>
<td>1st</td>
<td>1st</td>
</tr>
<tr>
<td><strong>Used for ART initiation</strong></td>
<td>1st or 2nd</td>
<td>No</td>
<td>1st or 2nd</td>
<td>1st</td>
<td>1st</td>
</tr>
<tr>
<td><strong>Start regimen</strong></td>
<td>1st or 2nd</td>
<td>No</td>
<td>1st or 2nd</td>
<td>1st</td>
<td>1st</td>
</tr>
<tr>
<td><strong>Line</strong></td>
<td>1st or 2nd</td>
<td>1st or 2nd</td>
<td>1st or 2nd</td>
<td>1st</td>
<td>1st</td>
</tr>
<tr>
<td><strong>Prescriber level</strong></td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td><strong>Tail</strong> needed</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td><strong>Contraindications</strong></td>
<td>• Renal failure</td>
<td>• Anaemia &lt;8g/dl</td>
<td>• ABC hypersensitivity</td>
<td>• ABC hypersensitivity</td>
<td>• ABC hypersensitivity</td>
</tr>
<tr>
<td><strong>Possible adverse reaction</strong></td>
<td>• Renal failure</td>
<td>• Insomnia, headache, nausea, diarrhoea i</td>
<td>• Epilepsy i</td>
<td>• History of psychosis</td>
<td>• Treatment failure g</td>
</tr>
<tr>
<td><strong>If confirmed, use Alt 1</strong></td>
<td>15c</td>
<td>4</td>
<td>1</td>
<td>15c</td>
<td>5</td>
</tr>
<tr>
<td><strong>If confirmed, use Alt 2</strong></td>
<td>14</td>
<td>(8)</td>
<td>(7)</td>
<td>TDF/3TC + RAL</td>
<td>(9)</td>
</tr>
</tbody>
</table>

---

a Mild skin rash and/or dizziness and nightmares are common after starting EFV. This usually resolves by itself and is not usually a reason to interrupt or change regimen.
b EFV can cause breast enlargement in children and men (one side or both sides). This may resolve spontaneously while continuing EFV, but substitution is usually needed (and effective).
c Do not combine ATV/r with rifampicin (TB treatment).

d Do not start patients with pre-existing jaundice or suspected hepatitis on ATV/r. Use LPV/r instead.
e ATV/r can cause jaundice. Mostly, this is only of cosmetic concern. Refer jaundice to a specialist for LFT. If only indirect bilirubin is raised, continue ATV. Stop ATV/r if LFT cannot be done.
f Treatment failure on 2nd line ART and DTG-based regimens need confirmation of resistance mutations by genotyping before switch can be considered.
g Fever, body pains, vomiting, cough / sore throat and breathing problems can be due to life-threatening ABC hypersensitivity (rare). Stop all ARVs immediately. Never re-start ABC.
h DTG should not be combined with standard antiepileptic drugs: carbamazepine, phenobarbital, phenytoin. Use non-DTG based regimen if possible. Else, consider phenobarbital or carbamazepine with double dose of DTG. Check VL 6-monthly to confirm suppression.
i DTG and RAL are very well tolerated. Mild headache, insomnia, nausea and diarrhoea usually subside without regime change.
j DTG and RAL may worsen liver damage (alcohol, viral Hepatitis B or C, etc.) and rarely cause hepatotoxicity. Check transaminases before and after starting DTG in patients with known Hep B/C.
k ABC/3TC/DTG 600/300/50mg will become available as fixed-dose combination in 2020.
<table>
<thead>
<tr>
<th>Drug</th>
<th>Tablets per tin Paed. Adult</th>
<th>3 – 3.9 kg</th>
<th>4 – 5.9 kg</th>
<th>6 – 9.9 kg</th>
<th>10 – 13.9 kg</th>
<th>14 – 19.9 kg</th>
<th>20 – 24.9 kg</th>
<th>25 – 29.9 kg</th>
<th>30 – 34.9 kg</th>
<th>35 – 39.9 kg</th>
<th>40 – 49.9 kg</th>
<th>50 kg +</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>AM PM</td>
<td>AM PM</td>
<td>AM PM</td>
<td>AM PM</td>
<td>AM PM</td>
<td>AM PM</td>
<td>AM PM</td>
<td>AM PM</td>
<td>AM PM</td>
<td>AM PM</td>
<td>AM PM</td>
</tr>
<tr>
<td>AZT / 3TC</td>
<td>60 / 60</td>
<td>1 1 1 1</td>
<td>1½ 1½</td>
<td>2 2</td>
<td>2½ 2½</td>
<td>3 3</td>
<td>1 1</td>
<td>1 1</td>
<td>1 1</td>
<td>1 1</td>
<td>1 1</td>
<td>1 1</td>
</tr>
<tr>
<td>ABC / 3TC</td>
<td>60 / 60</td>
<td>1 0 1 0</td>
<td>1½ 0</td>
<td>2 0</td>
<td>2½ 0</td>
<td>3 0</td>
<td>1 0</td>
<td>1 0</td>
<td>1 0</td>
<td>1 0</td>
<td>1 0</td>
<td>1 0</td>
</tr>
<tr>
<td>ABC / 3TC / DTG</td>
<td>60</td>
<td>1 0 1 0</td>
<td>1½ 1½</td>
<td>2 2</td>
<td>2½ 2½</td>
<td>3 3</td>
<td>1 1</td>
<td>1 1</td>
<td>1 1</td>
<td>1 1</td>
<td>1 1</td>
<td>1 1</td>
</tr>
<tr>
<td>LPV / r liquid / tabs</td>
<td>60 / 120</td>
<td>1ml</td>
<td>1ml</td>
<td>1.5ml</td>
<td>1.5ml</td>
<td>2 1</td>
<td>2 1</td>
<td>2 2</td>
<td>2 2</td>
<td>3 3</td>
<td>3 3</td>
<td>3 3</td>
</tr>
<tr>
<td>LPV/r granules (sachets)</td>
<td>120</td>
<td>2 2</td>
<td>2 2</td>
<td>3 3</td>
<td>4 4</td>
<td>5 5</td>
<td>6 6</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EFV</td>
<td>30 / 30</td>
<td>0 1</td>
<td>0 1½</td>
<td>0 1½</td>
<td>0 2</td>
<td>0 2</td>
<td>0 1</td>
<td>0 1</td>
<td>0 1</td>
<td>0 1</td>
<td>0 1</td>
<td>0 1</td>
</tr>
<tr>
<td>ATV / r</td>
<td>30 / 30</td>
<td>0 1</td>
<td>0 1½</td>
<td>0 1½</td>
<td>0 2</td>
<td>0 2</td>
<td>0 1</td>
<td>0 1</td>
<td>0 1</td>
<td>0 1</td>
<td>0 1</td>
<td>0 1</td>
</tr>
<tr>
<td>TDF / 3TC</td>
<td>30 / 30</td>
<td>0 1</td>
<td>0 1½</td>
<td>0 1½</td>
<td>0 2</td>
<td>0 2</td>
<td>0 1</td>
<td>0 1</td>
<td>0 1</td>
<td>0 1</td>
<td>0 1</td>
<td>0 1</td>
</tr>
<tr>
<td>TDF / 3TC / EFV</td>
<td>30 / 30</td>
<td>0 1</td>
<td>0 1½</td>
<td>0 1½</td>
<td>0 2</td>
<td>0 2</td>
<td>0 1</td>
<td>0 1</td>
<td>0 1</td>
<td>0 1</td>
<td>0 1</td>
<td>0 1</td>
</tr>
<tr>
<td>TDF / 3TC / DTG</td>
<td>30 / 90</td>
<td>1 0</td>
<td>1 0</td>
<td>1 0</td>
<td>1 0</td>
<td>1 0</td>
<td>1 0</td>
<td>1 0</td>
<td>1 0</td>
<td>1 0</td>
<td>1 0</td>
<td>1 0</td>
</tr>
<tr>
<td>DTG 50</td>
<td>30 / 90</td>
<td>0 1</td>
<td>0 1½</td>
<td>0 1½</td>
<td>0 2</td>
<td>0 2</td>
<td>0 1</td>
<td>0 1</td>
<td>0 1</td>
<td>0 1</td>
<td>0 1</td>
<td>0 1</td>
</tr>
<tr>
<td>DRV</td>
<td>60 / 60</td>
<td>1 1</td>
<td>1 1</td>
<td>1 1</td>
<td>1 1</td>
<td>1 1</td>
<td>1 1</td>
<td>1 1</td>
<td>1 1</td>
<td>1 1</td>
<td>1 1</td>
<td>1 1</td>
</tr>
<tr>
<td>r</td>
<td>60 / 60</td>
<td>2 1</td>
<td>2 2</td>
<td>2 2</td>
<td>3 3</td>
<td>3 3</td>
<td>3 3</td>
<td>3 3</td>
<td>3 3</td>
<td>3 3</td>
<td>3 3</td>
<td>3 3</td>
</tr>
<tr>
<td>ETV</td>
<td>120 / 120</td>
<td>2 2</td>
<td>2 2</td>
<td>2 2</td>
<td>3 3</td>
<td>3 3</td>
<td>3 3</td>
<td>3 3</td>
<td>3 3</td>
<td>3 3</td>
<td>3 3</td>
<td>3 3</td>
</tr>
<tr>
<td>RAL</td>
<td>60 / 60</td>
<td>2 2</td>
<td>2 2</td>
<td>3 3</td>
<td>4 4</td>
<td>4 4</td>
<td>4 4</td>
<td>4 4</td>
<td>4 4</td>
<td>4 4</td>
<td>4 4</td>
<td>4 4</td>
</tr>
<tr>
<td>CTX 120</td>
<td>1000 / 1000</td>
<td>0 1</td>
<td>0 1½</td>
<td>0 1½</td>
<td>0 2</td>
<td>0 2</td>
<td>0 1</td>
<td>0 1</td>
<td>0 1</td>
<td>0 1</td>
<td>0 1</td>
<td>0 1</td>
</tr>
<tr>
<td>INH 100</td>
<td>100 / 100</td>
<td>0 ½</td>
<td>0 ½</td>
<td>0 ½</td>
<td>0 1</td>
<td>0 1½</td>
<td>0 2</td>
<td>0 2</td>
<td>0 2</td>
<td>0 2</td>
<td>0 2</td>
<td>0 2</td>
</tr>
<tr>
<td>CTX 480</td>
<td>1000 / 1000</td>
<td>0 ½</td>
<td>0 ½</td>
<td>0 ½</td>
<td>0 1</td>
<td>0 1½</td>
<td>0 2</td>
<td>0 2</td>
<td>0 2</td>
<td>0 2</td>
<td>0 2</td>
<td>0 2</td>
</tr>
<tr>
<td>CTX 960</td>
<td>1000 / 1000</td>
<td>0 ½</td>
<td>0 ½</td>
<td>0 ½</td>
<td>0 1</td>
<td>0 1½</td>
<td>0 2</td>
<td>0 2</td>
<td>0 2</td>
<td>0 2</td>
<td>0 2</td>
<td>0 2</td>
</tr>
<tr>
<td>INH 300 (daily for IPT)</td>
<td>672</td>
<td>0 1</td>
<td>0 1½</td>
<td>0 1½</td>
<td>0 2</td>
<td>0 2</td>
<td>0 2</td>
<td>0 2</td>
<td>0 2</td>
<td>0 2</td>
<td>0 2</td>
<td>0 2</td>
</tr>
<tr>
<td>INH 300 (weekly for 3HP)</td>
<td>672</td>
<td>0 1</td>
<td>0 1½</td>
<td>0 1½</td>
<td>0 2</td>
<td>0 2</td>
<td>0 2</td>
<td>0 2</td>
<td>0 2</td>
<td>0 2</td>
<td>0 2</td>
<td>0 2</td>
</tr>
<tr>
<td>RFP 150 (weekly for 3HP)</td>
<td>24</td>
<td>0 3</td>
<td>0 4</td>
<td>0 5</td>
<td>0 5</td>
<td>0 5</td>
<td>0 5</td>
<td>0 5</td>
<td>0 5</td>
<td>0 5</td>
<td>0 5</td>
<td>0 6</td>
</tr>
</tbody>
</table>
14 Combining ART and TB treatment

- DTG- and RAL-based regimens (13, 14, 15 and 16) are a good combination with TB 1st line treatment.
  - However, the daily dose of DTG and RAL needs to be doubled while on rifampicin-containing TB treatment:
    - Take the regular DTG-containing regimen in the morning and one additional tablet of DTG 50mg in the evening (after 12 hours).
    - Take double the regular RAL-dose regimen in the morning and in the evening.
    - The doubling of DTG and RAL also applies to children.
  - Continue with double-dose DTG and RAL for 7 days after the last dose of rifampicin.

15 Continuing ART

15.7 Achieving optimal adherence

15.7.3 Supporting children on LPV/r granules

- Try to identify 2 or more guardians to ensure uninterrupted and reliable adherence support. Small children are completely reliant on a guardian to take their ARVs.
- Teach the guardians how to give LPV/r granules. Use the standard national job aid and education material.
  - LPV/r granules taste bitter when kept in the mouth for more than a few seconds. Give quickly after mixing with food.
  - Make sure guardians understand that both parts of the regimen have to be given together at the same time (e.g. ABC/3TC + LPV/r).
- Carefully check the child’s weight at each visit and adjust the dose based on Table 12 on page 16.
- Offer alternative regimens if the family is not able to cope with LPV/r granules and if additional support has not resulted in good adherence.
- Consult the DHA for any paediatric treatment challenges, including children suspected to be failing on PI- or DTG-based regimens.
15.10 Monitoring for treatment failure / HIV drug resistance

15.10.2 Viral load (VL) testing

Key Facts: Viral load testing

- The VL monitoring schedule is designed to detect ART failure early while avoiding unnecessary tests to save cost.

- Collect the first scheduled VL after 6 months on ART. Normally, patients are expected to have an undetectable VL at this time. If the VL is detectable, investigate:
  - Patients who were infected with drug-resistant HIV.
  - Patients who developed drug-resistance from previous ARV use (e.g. infants who received NVP prophylaxis).
  - Otherwise, a high VL at 6 months can be an important sign for poor adherence.

- After that, patients who are adherent and clinically well have a low risk of ART failure. Therefore, routine VL monitoring is scheduled approximately every 12 months from the last test.

- Collect missed VL tests at the next regular visit.

- Do additional targeted VL tests outside of this schedule when suspecting ART failure.

- Explain the standard VL monitoring schedule to every patient. Ask the patient to help remember when VL is due.
  - Explain (example): “You had your viral load drawn in November. Therefore, every November ASK your provider for your viral load test to be done.”

- Actively communicate (phone / home visit) any detectable VL results (above detection limit, even if <1000) to patients as soon as the result is received at the site. Call for an early appointment.

- DBS and plasma VL samples produce different results in the low ranges below 839 copies/ml:
  - DBS results are usually not quantifiable below 839 copies/ml. (Some labs may produce an actual readout above 400 copies/ml from DBS). A DBS result <839 copies/ml means that some virus has been detected, but it is not possible to determine if this VL is in the very low range below 40 copies/ml or higher.
  - Plasma results are usually quantified above 40 copies/ml.
  - Both DBS and plasma results of <LDL mean that no virus has been detected, i.e. the VL is undetectable or fully suppressed.
  - Plasma is the gold-standard for viral load testing. Collect plasma samples if possible.
When to do VL

- Routinely collect the next VL sample when **11 months or more** have elapsed since the last VL sample was collected.

- Don’t delay a scheduled/routine or targeted viral load sample collection because of (suspected) poor adherence.

- Ascertain **good** adherence in the last **3 months** before taking the follow-up sample after a high VL.
  - Review pill counts and doses missed carefully. Discuss openly to understand the true circumstances.
  - Trust the patient if they insist that adherence was good. Do not rely on pill count alone.

- Delay collection of follow-up sample after IAC ONLY if poor adherence is confirmed and if the patient is still clinically stable.

- See **Figure 6 on page 23** for the alignment of the VL monitoring schedule and 6 month dispensing.

Interpreting and acting on VL results

- See **Figure 5 on page 22** for indication, interpretation and action for VL testing.

<table>
<thead>
<tr>
<th>Table 13 (new): Classification of DBS and plasma VL results</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Sample type</strong></td>
</tr>
<tr>
<td>DBS</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Plasma</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>
### Successful ART

<table>
<thead>
<tr>
<th>Finding</th>
<th>Routine or targeted / repeat VL “suppressed”</th>
</tr>
</thead>
<tbody>
<tr>
<td>Interpretation</td>
<td>Successful ART</td>
</tr>
<tr>
<td>Action</td>
<td>Praise the patient and encourage further good adherence. Continue on the same regimen. Offer 6 month dispensing if otherwise eligible. Next routine VL after 12 months.</td>
</tr>
</tbody>
</table>

### Potential treatment failure

<table>
<thead>
<tr>
<th>Finding</th>
<th>Routine, Targeted/ repeat or Follow-up VL: “low-level viraemia”</th>
</tr>
</thead>
<tbody>
<tr>
<td>Interpretation</td>
<td>Potential treatment failure</td>
</tr>
<tr>
<td>Action</td>
<td>Deliver one quality session of intensive adherence counselling at the same visit when returning the result to the patient. Provide additional IAC sessions at 1 month intervals for patients with specific adherence problems. Enter in “Detectable Viral Load” register (green cover, prev. “High VL register”). Continue same ART regimen. Give a regular 3-month appointment. Collect repeat VL sample after 3 months of good adherence. Repeat the cycle if follow-up result is “low-level viraemia”.</td>
</tr>
</tbody>
</table>

### Confirmed treatment failure

<table>
<thead>
<tr>
<th>Finding</th>
<th>Targeted / repeat VL: “viraemia 1000+” AND Patient is on NNRTI-based regimen (0, 2, 4, 5, 6, 17) AND good adherence in the 3 months before sample collection</th>
</tr>
</thead>
<tbody>
<tr>
<td>Interpretation</td>
<td>The virus is likely resistant to the current ART regimen.</td>
</tr>
<tr>
<td>Action</td>
<td>Deliver one quality session of intensive adherence counselling at the same visit when returning the result to the patient. Provide additional IAC sessions at 1 month intervals for patients with specific adherence problems. Enter in “Detectable Viral Load” register (green cover, prev. “High VL register”). Consult certified 2nd Line Prescriber for initiation of 2nd line ART without delay. ‘Reset the clock’ for routine VL monitoring: 6 months after switch to 2nd or 3rd line and every 12 months thereafter.</td>
</tr>
</tbody>
</table>
Poor adherence or treatment failure

<table>
<thead>
<tr>
<th>Finding</th>
<th>Targeted / repeat VL: “viraemia 1000+” AND Patient is on PI- or DTG-based regimen (7, 8, 9, 10, 11, 12, 13, 14, 15, 16)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Interpretation</td>
<td>High VL on these regimens can be adherence problems / poor absorption or drug-resistant virus. Need genotype to confirm resistance before changing regimen.</td>
</tr>
<tr>
<td>Action</td>
<td>Deliver one quality session of intensive adherence counselling at the same visit when returning the result to the patient. Provide additional IAC sessions at 1 month intervals for patients with specific adherence problems. Enter in “Detectable Viral Load” register (green cover, prev. “High VL register”). Collect DBS or plasma sample for genotyping. Consult certified 2nd Line Prescriber and/or call the HIV Dept. hotline to organize resistance testing. Continue on current regimen until genotyping results are available. Give a regular 3-month appointment. Select ART regimen based on resistance profile. ‘Reset the clock’ for routine VL monitoring: 6 months after switch to 2nd or 3rd line and every 12 months thereafter.</td>
</tr>
</tbody>
</table>

**Updating VL results in the electronic medical record system**

- Enter as “839” for <839 copies/ml if the system does not provide qualifiers (<, >, =)
- Enter at “40” for <40 copies/ml if the system does not provide qualifiers (<, >, =)
Figure 5: Indication, interpretation and action for routine scheduled and targeted VL testing

When to do VL

- **ART clinic visit**
  - **Time since ART start**
    - Less than 6 months
    - 6 months or more
  - **Previous VL**
    - Less than 11 months ago
    - 11 months or more ago
    - *Never (1)*
  - **Clinical Condition**
    - **Well**
    - **Not Well (2)**
  - **Collect VL Sample**
    - Wait
    - Routine scheduled

Result and Action

- **VL Result**
  - Low-level viraemia or viraemia 1000+
    - Suppressed
  - Potential Failure
    - Successful ART
    - Intensive Adh. Support
    - Continue current regimen
- **Targeted/ Follow-up VL**

- **VL Result (copies / ml)**
  - Viraemia 1000+
    - Suppressed
  - Low-level viraemia
    - **Current Regimen**
      - 0, 2, 4, 5, 6, 17
        - Confirmed Failure
        - Start 2nd Line
      - 7 - 16
        - Poor adherence or failure
        - Genotype testing
    - Potential Failure
      - Intensive Adh. Support
      - Continue current regimen
    - Successful ART

(1) Includes: VL never tested, sample rejected, lost, or declared missing.
(2) Any of the following: Significant unintended weight loss, failure to thrive, new/worsening HIV-related disease (suspected or confirmed)
16 Differentiated ART services

16.1 Six months ARV dispensing (6MD) visits

Facility criteria

- Sites can provide 6MD when they meet the facility criteria:
  - Stable and reliable stock management for all HIV related commodities.
  - Secure storage space for additional large volumes of commodities: identify and organize room for storage in advance before the stocks arrive.
  - Ample current stocks for each ARV and other drugs needed (CPT, fluconazole, etc.) to avoid the need for rationing supplies for other patients.

Patient criteria

- Routinely give 6MD appointments for stable and adherent patients. Patients must meet all of the following criteria:
  - At least 24 years old; ages 18-24 are eligible if they have a dedicated treatment supporter recognised by the clinic.
  - On ART treatment for at least 6 months
  - On the current ART regimen for at least 3 months
  - Not on TPT (IPT or 3HP)
  - No current ARV side effects
  - No opportunistic infections
  - Suppressed VL in the last 12 months (<LDL or <40 copies/ml)
  - No pending VL result
  - Not pregnant or breastfeeding

- Figure 6 shows how to align 6MD appointments with the standard VL monitoring schedule.
- Plan ahead: give potentially a shorter appointment to maintain around 12 months between collection of VL samples.

Figure 6: Alignment of 6 months dispensing with 12-monthly VL monitoring
19 Transition to new ART regimen

Key Facts: 2\textsuperscript{nd} Phase of regimen transition

- The 2\textsuperscript{nd} Phase of regimen transition is for children previously on NNRTI-based regimens and for patients on PI-based 1\textsuperscript{st} and 2\textsuperscript{nd} line regimens.
- All NVP-based regimens (0P, 0A, 2P, 2A, 6A) will be phased out completely by 2\textsuperscript{nd} half of 2020.
- Transition of existing patients from other 1\textsuperscript{st} and 2\textsuperscript{nd} line regimens to DTG-based regimens:
  - Early experience from the DTG transition has shown that it is safer to confirm viral load suppression on the previous regimen before moving to a DTG-based regimen.
  - See updates in Section 19.2

19.2 Transition for patients currently on ART

- Explain to all patients the Key Facts about DTG
- Emphasize that other medicines and supplements containing cations (calcium, magnesium, zinc, iron, aluminium) must not be taken at the same time as DTG-based ART regimens (13, 14, 15) because this reduces DTG absorption. Such medicines include FeFol, antacids, multivitamin supplements.
  - Take DTG-based ARVs 2 hours before or 6 hours after such medicines.
- Patients who are yet to be transitioned need a suppressed VL result from within 6 months before transition to the new regimen.
  - Provide intensive adherence support and follow-up (FUP) VL for patients with potential or confirmed failure.
  - Proceed with routine transition only if the follow-up VL is suppressed.
  - Follow normal VL interpretation and switch to appropriate 2\textsuperscript{nd} line if failure is confirmed.

Routine transition of children to 13A once they reach 30kg+

- Monitor weight at each visit
- When the child has reached 30kg+:
  - Collect extraschedular VL sample (unless VL from the last 6 months is already available).
    - VL is suppressed: move to 13A
    - VL is low-level viraemia or viraemia 1000+: provide intensive adherence support, follow up for suspected failure.
- See Figure 7 for details of the 2019 / 2020 regimen transition strategy.
Figure 7: Regimen transition for all remaining children, women and men in 2019/2020

### 2019/2020 Regimen Transition: All remaining children, women and men

<table>
<thead>
<tr>
<th>Old Regimens</th>
<th>Conditions</th>
<th>New Regimens</th>
<th>Alternatives / Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Paediatric Regimens</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0P: ABC / 3TC + NVP</td>
<td>3 – 19.9kg (Can swallow whole tabs)</td>
<td>9P: ABC / 3TC + LPV/r Granules</td>
<td>Non-Standard</td>
</tr>
<tr>
<td>2P: AZT / 3TC / NVP</td>
<td></td>
<td>9P: ABC / 3TC + LPV/r Paed tabs</td>
<td>Best alternative if RAL is available</td>
</tr>
<tr>
<td>4P: AZT / 3TC + EFV</td>
<td></td>
<td></td>
<td>Double RAL dose in combination with TB treatment</td>
</tr>
<tr>
<td>11P: AZT / 3TC + LPV/r</td>
<td>20 – 24.9kg</td>
<td>15P: ABC / 3TC + DTG</td>
<td>May cause nausea / diarrhoea</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Must be 10kg + Can combine with TB treatment</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Under 10kg + Call DHA for options</td>
</tr>
<tr>
<td><strong>Adult Regimens</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0A: ABC / 3TC + NVP</td>
<td></td>
<td>15A: ABC / 3TC / DTG</td>
<td>For patients previously on 1st line who can’t take DTG</td>
</tr>
<tr>
<td>9A: ABC / 3TC + LPV/r</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8A: AZT / 3TC + ATV/r</td>
<td></td>
<td>17A: ABC / 3TC + EFV</td>
<td>For patients previously on 1st line who can’t take TDF and DTG</td>
</tr>
<tr>
<td>11A: AZT / 3TC + LPV/r</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10A: TDF / 3TC + ATV/r</td>
<td></td>
<td>7A, 8A, 9A, 10A, 11A</td>
<td>PI-based regimens remain as 1st line alternative and 2nd line options</td>
</tr>
<tr>
<td>5A: TDF / 3TC / EFV</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6A: TDF / 3TC + NVP</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2A: AZT / 3TC / NVP</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4A: AZT / 3TC + EFV</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

1) 15P consists of paediatric ABC/3TC (120/60mg) + regular adult DTG (50mg)
2) 15A will be available as fixed dose combination ABC/3TC/DTG, but can also be given as ABC/3TC + DTG
3) Confirm undetectable VL within last 6 months before transition

---

The regimen transition begins with confirming undetectable VL in the last 6 months before transition, followed by the use of TDF if contraindication of DTG.
Pre-exposure prophylaxis (PrEP)

- PrEP is now approved for roll-out as a public health intervention for HIV prevention in Malawi.
- Offer PrEP as an additional primary prevention method for HIV negative persons at substantial risk of acquiring HIV (see separate PrEP guidelines)
  - Emphasize the need for combination with other prevention methods such as consistent condom use, VMMC, etc.
- PrEP involves:
  - Taking one daily fixed-dose combination tablet of ARVs.
  - Quarterly HIV testing
  - Quarterly STI screening
  - Quarterly adherence support
  - Renal function monitoring

- Eligibility criteria for PrEP:
  - Confirmed HIV negative status
  - At substantial high risk of HIV acquisition
  - Body weight 30kg+
- TDF/3TC is the preferred PrEP regimen for Malawi.
  - Tenofovir/emtricitabine (TDF/FTC) can be given as an alternative.
- More details on PrEP are included in the upcoming PrEP guidelines for Malawi to be released this year.